BioCardia, Inc.
BioCardia, Inc. (BCDA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bcda · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for BioCardia, Inc. (BCDA) measures how much investors pay for each dollar of the company's trailing earnings. BCDA's current PE ratio of N/A is calculated by dividing its stock price of $0.92 by its TTM earnings per share of -$0.72.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 5 fiscal years · Front-end computedMinQ1 · 25%14.0x
MedianQ3 · 75%229.1x
Max
At N/A, BCDA's current P/E is lower than in 0% of its annual fiscal year readings over the past 5 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BioCardia, Inc.You BCDA | $5M | N/A | — | -$0.72 |
 Acurx Pharmaceuticals, Inc. ACXP | $3M | N/A | — | -$5.31 |
 Adial Pharmaceuticals, Inc. ADIL | $2M | N/A | — | -$11.93 |
 Alzamend Neuro, Inc. ALZN | $4M | N/A | — | -$11.34 |
 Aprea Therapeutics, Inc. APRE | $5M | N/A | — | -$1.93 |
 Aptevo Therapeutics Inc. APVO | $11M | N/A | — | -$8230.43 |
 Creative Medical Technology Holdings, Inc. CELZ | $6M | N/A | — | -$2.52 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.23 | — | |
2024-12-31 FY2024 | — | $-2.90 | — | |
2023-12-31 FY2023 | — | $-8.19 | — | |
2022-12-31 FY2022 | — | $-10.08 | — | |
2021-12-31 FY2021 | — | $-11.19 | — | |
2020-12-31 FY2020 | — | $-22.24 | — | |
2019-12-31 FY2019 | — | $-39.09 | — | |
2018-12-31 FY2018 | — | $-49.20 | — | |
2017-12-31 FY2017 | — | $-43.54 | — | |
2016-12-31 FY2016 | — | $-166.33 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BioCardia, Inc. (BCDA) measures how much investors pay for each dollar of the company's trailing earnings. BCDA's current PE ratio of N/A is calculated by dividing its stock price of $0.92 by its TTM earnings per share of -$0.72.
Frequently asked questions
BCDA pe ratio · 6 questionsBCDA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.92 and TTM EPS of -$0.72. Data sourced from Financial Modeling Prep via BCDA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BioCardia, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09